This inventor holds 1 USPTO granted patent and 6 published patent applications and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018
Title: **Inventor Spotlight: Craig Basson**
Introduction
Craig Basson, a notable inventor based in Needham, MA, has made significant contributions to the medical field through his innovative approach to treating peripheral arterial disease (PAD). With one patent to his name, he exemplifies the spirit of innovation that drives progress in healthcare.
Latest Patents
His patent, titled "Use of IL-1β binding antibodies for treating peripheral arterial disease," focuses on a method for alleviating symptoms of PAD. The invention outlines a treatment regimen involving the administration of approximately 25 mg to 300 mg of an IL-1β binding antibody or a functional fragment thereof. This groundbreaking work holds promise in improving the quality of life for individuals affected by this condition.
Career Highlights
Craig Basson is affiliated with Novartis AG, a leading global healthcare company. His role within the organization highlights his commitment to advancing medical science and developing innovative treatments. His expertise in therapeutic strategies showcases his dedication to addressing complex health issues.
Collaborations
Throughout his career, Craig has collaborated with esteemed colleagues such as Mark C. Fishman and Tom Thuren. These partnerships not only foster a creative working environment but also enhance the scope and impact of their research endeavors. Collaborative efforts within Novartis AG have the potential to drive significant advancements in therapeutic applications.
Conclusion
In summary, Craig Basson represents a unique blend of innovation and expertise in the pharmaceutical industry. His patent on IL-1β binding antibodies signifies a crucial advancement in the treatment of peripheral arterial disease. As he continues his work at Novartis AG alongside talented colleagues, the future holds great potential for further breakthroughs in healthcare solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile